Evidence map›Paper›PMID 42499675›Full record

ArticleActa naturae

Isolation of Monoclonal Neutralizing Single-Domain Antibodies Against Clostridioides difficile Toxin B.

I A Alekseeva, A S Ungur, I A Favorskaya, A I Tukhvatulin, D V Shcheblyakov, A I Korobkova, M E Komyakova, O L Voronina, N N Ryzhova, E I Ermolova and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

I A AlekseevaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
A S UngurGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
I A FavorskayaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
A I TukhvatulinGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
D V ShcheblyakovGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
A I KorobkovaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
M E KomyakovaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
O L VoroninaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
N N RyzhovaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
E I ErmolovaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
M S KundaGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
D Yu LogunovGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
M M BobrovaCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency, Moscow, 119121 Russia.
V V MakarovCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency, Moscow, 119121 Russia.
S M YudinCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical and Biological Agency, Moscow, 119121 Russia.
A L GintsburgGamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation, Moscow, 123098 Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Clostridioides difficile infection (CDI) is one of the most common nosocomial infections around. The key pathogenicity factors of this bacterium include the toxins A and B that cause the disease symptoms. Neutralization of these toxins is one of the promising strategies for CDI treatment. Here, we isolated a panel of single-domain antibodies to the toxin B CROPs domain. Two antibodies, TB5A7 and TB4A8, exhibiting potent neutralizing activity were modified to produce homodimeric forms. The TB5A7 and TB4A8 dimers were characterized by enhanced neutralizing activity and protected animals from a toxin B lethal challenge. The obtained antibodies may be used to develop new agents for CDI treatment.

Indexed as

CDIClostridioides difficilesingle-domain antibodiesTcdBtoxin BVHH

Identifiers

PMID42499675
PMCPMC13399636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.